Selective kinase inhibitors have become an important class of anti-cancer agents. However, clinical success of these agents is mostly limited to a small subset of patients, who are often defined by specific genomic lesions within their tumor cells. Recent progress in cancer genetics and medicinal chemistry allows for the first time effective personalization of tumor therapy with so far unreached benefit for some patient populations.
展开▼
